## Natalia Rosso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4431351/publications.pdf Version: 2024-02-01



NATALIA ROSSO

#	Article	IF	CITATIONS
1	Global epidemiology of nonâ€alcoholic fatty liver disease/nonâ€alcoholic steatohepatitis: What we need in the future. Liver International, 2018, 38, 47-51.	1.9	297
2	Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterology, 2012, 12, 20.	0.8	109
3	Subcellular Localization of APE1/Ref-1 in Human Hepatocellular Carcinoma: Possible Prognostic Significance. Molecular Medicine, 2007, 13, 89-96.	1.9	93
4	Galectin-1 and Its Involvement in Hepatocellular Carcinoma Aggressiveness. Molecular Medicine, 2010, 16, 102-115.	1.9	69
5	The expression levels of the translational factors eEF1A 1/2 correlate with cell growth but not apoptosis in hepatocellular carcinoma cell lines with different differentiation grade. Biochimie, 2007, 89, 1544-1552.	1.3	62
6	The interplay between hepatic stellate cells and hepatocytes in an in vitro model of NASH. Toxicology in Vitro, 2015, 29, 1753-1758.	1.1	49
7	Hepatocyte-derived macrophage migration inhibitory factor mediates alcohol-induced liver injury in mice and patients. Journal of Hepatology, 2017, 67, 1018-1025.	1.8	48
8	In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease. Current Medicinal Chemistry, 2011, 18, 1079-1084.	1.2	45
9	An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. PLoS ONE, 2016, 11, e0158817.	1.1	45
10	Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterology, 2012, 12, 160.	0.8	44
11	Translational approaches: from fatty liver to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2014, 20, 9038-49.	1.4	43
12	Effects of E2F1–cyclin E1–E2 circuit down regulation in hepatocellular carcinoma cells. Digestive and Liver Disease, 2011, 43, 1006-1014.	0.4	42
13	The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Experimental and Molecular Pathology, 2015, 98, 85-92.	0.9	42
14	Hepatic cancer stem cells and drug resistance: Relevance in targeted therapies for hepatocellular carcinoma. World Journal of Hepatology, 2010, 2, 114.	0.8	42
15	Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World Journal of Gastroenterology, 2016, 22, 9096.	1.4	39
16	Gene Expression Analysis in HBV Transgenic Mouse Liver: A Model to Study Early Events Related to Hepatocarcinogenesis. Molecular Medicine, 2006, 12, 115-123.	1.9	31
17	Effects of Oral Administration of Silymarin in a Juvenile Murine Model of Non-alcoholic Steatohepatitis. Nutrients, 2017, 9, 1006.	1.7	28
18	Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model. Scientific Reports, 2020, 10, 1699.	1.6	26

NATALIA ROSSO

#	Article	IF	CITATIONS
19	Differentiation between stages of non-alcoholic fatty liver diseases using surface-enhanced Raman spectroscopy. Analytica Chimica Acta, 2020, 1110, 190-198.	2.6	25
20	Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: identification of six novel alleles. Neurogenetics, 2009, 10, 49-58.	0.7	22
21	Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates. International Journal of Molecular Sciences, 2022, 23, 2764.	1.8	22
22	Treatment of Human Fibroblasts Carrying NPC1 Missense Mutations with MG132 Leads to an Improvement of Intracellular Cholesterol Trafficking. JIMD Reports, 2011, 2, 59-69.	0.7	21
23	Alterations in the Cell Cycle in the Cerebellum of Hyperbilirubinemic Gunn Rat: A Possible Link with Apoptosis?. PLoS ONE, 2013, 8, e79073.	1.1	19
24	Sex differences in non-alcoholic fatty liver disease: hints for future management of the disease. , 2020, 1, 51-74.		18
25	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2014, 13, 113-120.	0.6	16
26	Optimization of Point-Shear Wave Elastography by Skin-to-Liver Distance to Assess Liver Fibrosis in Patients Undergoing Bariatric Surgery. Diagnostics, 2020, 10, 795.	1.3	15
27	Occult hepatitis B virus infection predicts nonâ€alcoholic steatohepatitis in severely obese individuals from Italy. Liver International, 2020, 40, 1601-1609.	1.9	11
28	The Pros and the Cons for the Use of Silybin-Rich Oral Formulations in Treatment of Liver Damage (NAFLD in Particular). Current Medicinal Chemistry, 2015, 22, 2954-2971.	1.2	9
29	Silybin Modulates Collagen Turnover in an In Vitro Model of NASH. Molecules, 2019, 24, 1280.	1.7	8
30	The Beneficial Effects of Triterpenic Acid and Acteoside in an In Vitro Model of Nonalcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences, 2022, 23, 3562.	1.8	8
31	Dissimilar expression of multidrug resistance <scp><i>mdr1</i></scp> and <scp><i>bcrp</i></scp> by the replication of hepatitis <scp>C</scp> virus: role of the nonstructural 5 <scp>A</scp> protein. Journal of Viral Hepatitis, 2013, 20, e127-30.	1.0	7
32	Taste perception and expression in stomach of bitter taste receptor tas2r38 in obese and lean subjects. Appetite, 2021, 166, 105595.	1.8	7
33	A simple in silico strategy identifies candidate biomarkers for the diagnosis of liver fibrosis in morbidly obese subjects. Liver International, 2018, 38, 155-163.	1.9	5
34	Kinetics of the inflammatory response induced by free fatty acid accumulation in hepatocytes. Annals of Hepatology, 2013, 13, 113-20.	0.6	5
35	Diagnostic management of nonalcoholic fatty liver disease: a transformational period in the development of diagnostic and predictive tools—a narrative review. Annals of Translational Medicine, 2021, 9, 727-727.	0.7	3

Role of MIF in Hepatic Inflammatory Diseases and Fibrosis. , 2017, , 109-134.

3

NATALIA ROSSO

#	Article	IF	CITATIONS
37	Targeted multicomponent polysomes for high efficiency, simultaneous anti-sense and gene delivery. Soft Matter, 2011, 7, 9424.	1.2	2
38	Ficolin-2 Plasma Level Assesses Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. International Journal of Molecular Sciences, 2022, 23, 2813.	1.8	2
39	Alcohol, liver and genes: an intricate puzzle. Annals of Hepatology, 2013, 12, 860.	0.6	1
40	Modifications of IGF2 and EGFR plasma protein concentrations in NAFLD patients after bariatric surgery. International Journal of Obesity, 2021, 45, 374-382.	1.6	1
41	Editorial: treatments for nonâ€alcoholic steatohepatitis ―still a long way to go. Alimentary Pharmacology and Therapeutics, 2017, 46, 700-701.	1.9	0
42	Alcohol, liver and genes: an intricate puzzle. Annals of Hepatology, 2013, 12, 860.	0.6	0